company background image
RAFA logo

Rafarma Pharmaceuticals OTCPK:RAFA Stock Report

Last Price

US$0.12

Market Cap

US$10.3m

7D

17.3%

1Y

-53.1%

Updated

12 Jan, 2025

Data

Company Financials

Rafarma Pharmaceuticals, Inc.

OTCPK:RAFA Stock Report

Market Cap: US$10.3m

RAFA Stock Overview

A multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. More details

RAFA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Rafarma Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Rafarma Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.12
52 Week HighUS$0.27
52 Week LowUS$0.033
Beta0
1 Month Change92.21%
3 Month Change101.77%
1 Year Change-53.10%
3 Year Change-85.34%
5 Year Change-64.90%
Change since IPO-95.31%

Recent News & Updates

Recent updates

Shareholder Returns

RAFAUS PharmaceuticalsUS Market
7D17.3%0.5%-2.1%
1Y-53.1%2.3%21.3%

Return vs Industry: RAFA underperformed the US Pharmaceuticals industry which returned 2.3% over the past year.

Return vs Market: RAFA underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is RAFA's price volatile compared to industry and market?
RAFA volatility
RAFA Average Weekly Movement32.4%
Pharmaceuticals Industry Average Movement11.1%
Market Average Movement6.4%
10% most volatile stocks in US Market18.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: RAFA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: RAFA's weekly volatility (32%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/an/arafarma.si

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders.

Rafarma Pharmaceuticals, Inc. Fundamentals Summary

How do Rafarma Pharmaceuticals's earnings and revenue compare to its market cap?
RAFA fundamental statistics
Market capUS$10.29m
Earnings (TTM)-US$117.22k
Revenue (TTM)US$133.33k

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RAFA income statement (TTM)
RevenueUS$133.33k
Cost of RevenueUS$133.33k
Gross ProfitUS$0
Other ExpensesUS$117.22k
Earnings-US$117.22k

Last Reported Earnings

Mar 31, 2012

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did RAFA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/12 04:58
End of Day Share Price 2025/01/10 00:00
Earnings2012/03/31
Annual Earnings2012/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rafarma Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution